Clinical efficacy and safety of full-dose versus half-dose corticosteroids plus leflunomide for IgA nephropathy

Abstract Background The results of leflunomide (LEF) in patients with IgA nephropathy (IgAN) were inconsistent. Methods A total of 149 kidney biopsy-confirmed IgAN patients with an estimated glomerular filtration rate (eGFR) ≥ 50 ml/min/1.73 m2 and protein excretion levels ≥0.75 g/d were enrolled, w...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yebei Li, Yi Xiong, Tianlun Huang, Xin Liu, Gaosi Xu
Formato:	article
Lenguaje:	EN
Publicado:	BMC 2021
Materias:	IgA nephropathy Leflunomide Corticosteroids Renin-angiotensin system blockers Diseases of the genitourinary system. Urology RC870-923
Acceso en línea:	https://doaj.org/article/3ac669d511744fb3ab929694e5bdec18
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:3ac669d511744fb3ab929694e5bdec18
record_format	dspace
spelling	oai:doaj.org-article:3ac669d511744fb3ab929694e5bdec182021-11-08T11:18:00ZClinical efficacy and safety of full-dose versus half-dose corticosteroids plus leflunomide for IgA nephropathy10.1186/s12882-021-02555-z1471-2369https://doaj.org/article/3ac669d511744fb3ab929694e5bdec182021-11-01T00:00:00Zhttps://doi.org/10.1186/s12882-021-02555-zhttps://doaj.org/toc/1471-2369Abstract Background The results of leflunomide (LEF) in patients with IgA nephropathy (IgAN) were inconsistent. Methods A total of 149 kidney biopsy-confirmed IgAN patients with an estimated glomerular filtration rate (eGFR) ≥ 50 ml/min/1.73 m2 and protein excretion levels ≥0.75 g/d were enrolled, with 65 subjects receiving half-dose CS plus LEF (LEF group), and the 84 counterpart patients accepting full-dose corticosteroid (Full CS group). The primary outcomes included the complete remission (CR) rates and incidence of adverse events (AEs). The secondary outcomes were the overall remission (OR) rates and a combined event (eGFR reduced ≥30%, end-stage renal disease [ESRD], hemodialysis, peritoneal dialysis or kidney transplantation). Results During the 18 months of follow-up, the CR rates were 72 and 64% in the LEF and Full CS groups (P = 0.299), respectively. The proportion of patients with OR rates in the LEF group and Full CS group was 89% versus 75%, respectively (P = 0.027). Serious AEs were observed only in the Full CS group (P = 0.017). The incidences of total AEs (P = 0.036) and infections (P = 0.024) were lower in the LEF group than in the Full CS group. Conclusions LEF combined with half-dose CS is superior to full-dose CS in the treatment of IgAN.Yebei LiYi XiongTianlun HuangXin LiuGaosi XuBMCarticleIgA nephropathyLeflunomideCorticosteroidsRenin-angiotensin system blockersDiseases of the genitourinary system. UrologyRC870-923ENBMC Nephrology, Vol 22, Iss 1, Pp 1-8 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	IgA nephropathy Leflunomide Corticosteroids Renin-angiotensin system blockers Diseases of the genitourinary system. Urology RC870-923
spellingShingle	IgA nephropathy Leflunomide Corticosteroids Renin-angiotensin system blockers Diseases of the genitourinary system. Urology RC870-923 Yebei Li Yi Xiong Tianlun Huang Xin Liu Gaosi Xu Clinical efficacy and safety of full-dose versus half-dose corticosteroids plus leflunomide for IgA nephropathy
description	Abstract Background The results of leflunomide (LEF) in patients with IgA nephropathy (IgAN) were inconsistent. Methods A total of 149 kidney biopsy-confirmed IgAN patients with an estimated glomerular filtration rate (eGFR) ≥ 50 ml/min/1.73 m2 and protein excretion levels ≥0.75 g/d were enrolled, with 65 subjects receiving half-dose CS plus LEF (LEF group), and the 84 counterpart patients accepting full-dose corticosteroid (Full CS group). The primary outcomes included the complete remission (CR) rates and incidence of adverse events (AEs). The secondary outcomes were the overall remission (OR) rates and a combined event (eGFR reduced ≥30%, end-stage renal disease [ESRD], hemodialysis, peritoneal dialysis or kidney transplantation). Results During the 18 months of follow-up, the CR rates were 72 and 64% in the LEF and Full CS groups (P = 0.299), respectively. The proportion of patients with OR rates in the LEF group and Full CS group was 89% versus 75%, respectively (P = 0.027). Serious AEs were observed only in the Full CS group (P = 0.017). The incidences of total AEs (P = 0.036) and infections (P = 0.024) were lower in the LEF group than in the Full CS group. Conclusions LEF combined with half-dose CS is superior to full-dose CS in the treatment of IgAN.
format	article
author	Yebei Li Yi Xiong Tianlun Huang Xin Liu Gaosi Xu
author_facet	Yebei Li Yi Xiong Tianlun Huang Xin Liu Gaosi Xu
author_sort	Yebei Li
title	Clinical efficacy and safety of full-dose versus half-dose corticosteroids plus leflunomide for IgA nephropathy
title_short	Clinical efficacy and safety of full-dose versus half-dose corticosteroids plus leflunomide for IgA nephropathy
title_full	Clinical efficacy and safety of full-dose versus half-dose corticosteroids plus leflunomide for IgA nephropathy
title_fullStr	Clinical efficacy and safety of full-dose versus half-dose corticosteroids plus leflunomide for IgA nephropathy
title_full_unstemmed	Clinical efficacy and safety of full-dose versus half-dose corticosteroids plus leflunomide for IgA nephropathy
title_sort	clinical efficacy and safety of full-dose versus half-dose corticosteroids plus leflunomide for iga nephropathy
publisher	BMC
publishDate	2021
url	https://doaj.org/article/3ac669d511744fb3ab929694e5bdec18
work_keys_str_mv	AT yebeili clinicalefficacyandsafetyoffulldoseversushalfdosecorticosteroidsplusleflunomideforiganephropathy AT yixiong clinicalefficacyandsafetyoffulldoseversushalfdosecorticosteroidsplusleflunomideforiganephropathy AT tianlunhuang clinicalefficacyandsafetyoffulldoseversushalfdosecorticosteroidsplusleflunomideforiganephropathy AT xinliu clinicalefficacyandsafetyoffulldoseversushalfdosecorticosteroidsplusleflunomideforiganephropathy AT gaosixu clinicalefficacyandsafetyoffulldoseversushalfdosecorticosteroidsplusleflunomideforiganephropathy
_version_	1718442226257756160

Clinical efficacy and safety of full-dose versus half-dose corticosteroids plus leflunomide for IgA nephropathy

Ejemplares similares